



## Michael D. Tucker

Shareholder

Birmingham | 205.244.3873 | [mdtucker@bakerdonelson.com](mailto:mdtucker@bakerdonelson.com)

Michael D. Tucker is a shareholder in the Firm's Birmingham office and practices corporate and health law.

Mr. Tucker's practice focuses on corporate and commercial contracts, mergers and acquisitions, joint ventures, and health care law. He represents clients in a wide range of industries including life sciences, real estate development and investment, private equity, and health care. He regularly advises clients on corporate formation, commercial contracts, joint ventures, acquisitions and divestitures of business and assets, licensing, clinical research, and health care matters.

An avid runner, Mr. Tucker can often be found on the roads and trails in and around Birmingham.



## Representative Matters

### Corporate and Private Equity

- Represented Communication Associates, Inc., a manufacturer of custom design RF components, in its sale to PPC Broadband, Inc.
- Represented Origin Editorial, LLC, a peer review and associated scholarly publishing services provider, in its sale to KnowledgeWorks Global Ltd.
- Represented privately-held U.S. real estate investment firm on multiple private equity fund formations.
- Represented privately-held U.S. real estate investment firm on multiple joint venture agreements with various development partners.
- Represented privately-held for-profit school in various tax credit transactions.
- Represented Canadian pension fund in the acquisition of interests in a U.S. portfolio of multi-family properties.
- Represented Canadian pension fund in the acquisition of interests in a U.S. portfolio of industrial properties.
- Represented Canadian investment manager in the acquisition of interests in a U.S. portfolio of multi-family properties.
- Represented specialty lender in acquisition and divestiture of manufactured home floor plan financing portfolio.
- Represented early-stage, oncology-focused life sciences company in private offering of securities.
- Represented drug development services provider in private offering of securities.
- Represented U.S. pharmaceutical manufacturer in asset dispositions of various branded over-the-counter products.
- Represented publicly traded hospital-focused real estate investment trust on numerous transactions ranging in value up to \$2 billion.

### Health Care and Life Sciences

- Represented clinical-stage sponsor in collaboration agreement for the development of a companion diagnostic product.
- Represent global pharmaceutical manufacturer in all aspects of U.S. and ex-U.S. clinical trials (phases I-III) for various oncology products including contract negotiations with contract research organizations (CRO) and other vendors and service providers.
- Represented urgent care practice management company in de novo formation and private offering of securities.

- Represented urgent care practice management company in corporate restructuring.
- Represented urgent care practice in de novo formation and regulatory compliance.
- Represented nationwide mail order pharmacy in de novo formation and recapitalization.
- Represented clinical diagnostic laboratory in corporate restructuring.
- Represented early-stage Israeli medical device company in a U.S. clinical trial for experimental breast cancer detection equipment.
- Represent dedicated clinical research site in its de novo formation, in contract negotiation with sponsors and vendors, and in all general corporate matters.
- Represent medical device manufacturer in all aspects of U.S. pilot and pivotal medical device clinical trials including contract negotiations with CROs and other vendors and service providers.
- Represented clinical-stage sponsor in phase I clinical trial for development of a cancer immunotherapy.
- Represented clinical-stage sponsor in Collaboration and Clinical Supply Agreement with large U.S. pharmaceutical manufacturer for development of cancer immunotherapies.
- Represented clinical-stage sponsor in Clinical Supply Agreement with large European pharmaceutical manufacturer for development of cancer immunotherapies.
- Represent large, multi-office, single-specialty medical practice in all aspects of clinical research contracting.
- Represented clinical trial site management organization in de novo formation.
- Represented U.S. biotechnology company in U.S. and ex-U.S. phases II and III global clinical trials for anti-viral therapy.
- Represented anatomic pathology laboratory in negotiation of master services agreement with CRO.



## Professional Honors & Activities

- Listed in *The Best Lawyers in America*® for Corporate Law (2025, 2026)
- Member – Alabama State Bar
- Member – American Health Law Association
- Member – American Bar Association



## Civic Involvement

- Member (Ex-Officio) – The University of Alabama at Birmingham, School of Health Professions, Dean's Advisory Board
- Member – Leadership UAB Class of 2010



## Publications

- "Is Your Pharmacy Compliant with the FDA's New Rules on Interstate Shipment of Compounded Drugs?," *Pharmaceutical Compliance Monitor* (September 2014)
- Featured – "Traps in the Compounding Quality Act – Don't get caught!," *Wolters Kluwer Health Law Daily Wrap Up*, Strategic Perspectives (July 2014)



## Speaking Engagements

- "Healthcare Contracts: Laws To Know And Potential Pitfalls To Avoid," 2019 Alabama Healthcare Fraud Summit, InfraGard Birmingham Members Alliance, Birmingham, Alabama (September 2019)
- "Survival Strategies for a Changing Health Care Economy," Auburn University Physician Executive MBA Program Alumni Reunion, Auburn, Alabama (October 2014)



## Education

- Tulane University Law School, J.D., 2008, magna cum laude

- *Tulane Law Review* – Managing Editor, 2007 – 2008 and Member, 2006 – 2007
- Birmingham-Southern College, B.S., 2005, magna cum laude, Phi Beta Kappa



## Admissions

- Alabama, 2008